Date | Price Target | Rating | Analyst |
---|---|---|---|
1/16/2024 | $17.00 → $17.50 | Buy → Neutral | Compass Point |
11/21/2023 | $17.00 | Neutral | UBS |
8/30/2023 | $17.50 | Neutral → Buy | Compass Point |
8/4/2023 | $13.50 → $17.00 | Underperform → Mkt Perform | Keefe Bruyette |
4/6/2023 | $16.00 | Neutral → Overweight | Piper Sandler |
3/13/2023 | $14.50 → $10.50 | Mkt Perform → Underperform | Keefe Bruyette |
7/29/2022 | Outperform → Perform | Oppenheimer | |
4/22/2022 | $18.00 | Outperform → Mkt Perform | Keefe Bruyette |
Q2 2024 Total Gross Debt and Equity Commitments of $686.5 Million Record Q2 2024 Total Gross Fundings of $461.5 Million, an Increase of 28.7% Year-over-Year Record Q2 2024 Total Investment Income of $125.0 Million, an Increase of 7.5% Year-over-Year Q2 2024 Net Investment Income "NII" of $82.4 Million, or $0.51 per Share, an Increase of 8.8% Year-over-Year Q2 2024 NII Provides 128% Coverage of the Base Cash Distribution Conservative Balance Sheet Management with Net GAAP Leverage of 93.3% and Net Regulatory Leverage of 83.9% Undistributed Earnings Spillover of $145.0 Million, or $0.89(1) per Ending Shares Outstanding Approximately $4.6 Billion of Assets Under Management, an In
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its second quarter 2024 financial results conference call for Thursday, August 1, 2024, at 2:00 p.m. PT (5:00 p.m. ET). Hercules will release its financial results after market close that same day. To participate via telephone, please register here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), will conduct its 2024 Annual Meeting of Stockholders by virtual meeting on Thursday, June 20, 2024 at 9:00 a.m. (Pacific Time). The proxy statement for the meeting was filed on April 23, 2024 and mailed to stockholders of record as of April 19, 2024. 2024 Annual Meeting of Stockholders June 20, 2024 at 9:00 a.m. Pacific Time Virtual Meeting via Internet: www.virtualshareholdermeeting.com/HTGC2024 Matters to be voted on include: 1) election of three independent directors, 2) an advisory vote on the compensation of the Company's named executive officers, 3) authorization of the Company to sell or issue shares of its common
SAUSALITO, Calif., Nov. 29, 2023 /PRNewswire/ -- Revelation Partners, a healthcare investment firm with over $1.5 billion of capital under management, announced today the addition of Andrew Olson as Partner, Chief Financial Officer and Chief Operating Officer. Mr. Olson has an extensive background in the venture capital and funds management industry. His addition to the team will enhance the firm's technical expertise, support the differentiated investment model, and strengthen the firm's ongoing foundation. As the firm's new Chief Financial Officer and Chief Operating Officer
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Nikos Theodosopoulos was appointed to serve as an independent member of its board of directors, effective September 21, 2023. Mr. Theodosopoulos is an experienced corporate executive and board director with more than 38 years in senior management roles in both the financial services and technology industries. Mr. Theodosopoulos will serve on the Company's Audit Committee. "Nikos' combined experienc
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that DeAnne Aguirre was appointed to serve as an independent member of its board of directors, effective June 23, 2022. Ms. Aguirre is an experienced corporate executive and Board Director with more than 30 years in senior leadership managing large and complex domestic and international business units. Ms. Aguirre will serve on the Nominating and Corporate Governance Committee. "As we continue to expand o
Compass Point downgraded Hercules Capital from Buy to Neutral and set a new price target of $17.50 from $17.00 previously
UBS initiated coverage of Hercules Capital with a rating of Neutral and set a new price target of $17.00
Compass Point upgraded Hercules Capital from Neutral to Buy and set a new price target of $17.50
SC 13G - Hercules Capital, Inc. (0001280784) (Subject)
SC 13G/A - Hercules Capital, Inc. (0001280784) (Filed by)
SC 13G - Hercules Capital, Inc. (0001280784) (Filed by)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
Facility adds operational flexibility and provides funding for the recently announced Phase 3 PEAK-1 study for casdatifan. $150 million committed, of which $50 million was drawn at closing and the remaining $100 million available at Arcus's sole discretion. Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported it has obtained a $250 million term loan facility from Hercules Capital, Inc. (NYSE:HTGC), a leader in customized debt financing for companies in life sciences and technology-related markets. The additional capital strengthens Arcus's
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Kroll Bond Rating Agency, Inc. ("KBRA") has reaffirmed Hercules' investment grade corporate and credit rating of BBB+. KBRA issued a statement announcing the reaffirmation of the rating and stable outlook, as well as its underlying analysis. "We are very pleased that KBRA has reaffirmed our BBB+ investment grade corporate and credit rating," stated Seth Meyer, chief financial officer of Hercules. "Th
Q2 2024 Total Gross Debt and Equity Commitments of $686.5 Million Record Q2 2024 Total Gross Fundings of $461.5 Million, an Increase of 28.7% Year-over-Year Record Q2 2024 Total Investment Income of $125.0 Million, an Increase of 7.5% Year-over-Year Q2 2024 Net Investment Income "NII" of $82.4 Million, or $0.51 per Share, an Increase of 8.8% Year-over-Year Q2 2024 NII Provides 128% Coverage of the Base Cash Distribution Conservative Balance Sheet Management with Net GAAP Leverage of 93.3% and Net Regulatory Leverage of 83.9% Undistributed Earnings Spillover of $145.0 Million, or $0.89(1) per Ending Shares Outstanding Approximately $4.6 Billion of Assets Under Management, an In
424B3 - Hercules Capital, Inc. (0001280784) (Filer)
8-K - Hercules Capital, Inc. (0001280784) (Filer)
8-K - Hercules Capital, Inc. (0001280784) (Filer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
5 analysts have expressed a variety of opinions on Hercules Capital (NYSE:HTGC) over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 4 1 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 3 1 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $20.5, a high estimate of $22.00, and a low estimate of $19.00. Observing a 3.54% increase, the current average has
Piper Sandler analyst Crispin Love maintains Hercules Capital (NYSE:HTGC) with a Overweight and raises the price target from $21.5 to $22.